Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

NVCTNVCT
10 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in NUVECTIS PHARMA INC

CITADEL ADVISORS LLC holds 115,532 shares of NVCT (NUVECTIS PHARMA INC), worth $2.1M as of 2026-Q2. The position was increased (+47.3% shares). NVCT represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$2.1M

Current Shares

115,532

Total Value Change

+$1.7M

Total Shares Change

+80,463

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
115,532
+47.3%
$2.1M0.0%$18.39
36
2026-Q1
New
78,425
-
$606,2250.0%$8.71
34
2025-Q2
Exited
0
-100.0%
$00.0%$7.55
0
2025-Q1
New
10,344
-
$101,0610.0%$10.46
33
2024-Q3
Exited
0
-100.0%
$00.0%$6.18
0
2024-Q2
New
14,937
-
$94,5510.0%$6.33
33
2023-Q3
Exited
0
-100.0%
$00.0%$12.89
0
2023-Q2
New
28,028
-
$447,6070.0%$16.34
33
2022-Q3
Exited
0
-100.0%
$00.0%$7.37
0
2022-Q2
New
35,069
-
$393,0000.0%$11.84
33

Other major holders of NVCT: BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used